New HotStart LAMP assay aims to simplify B virus detection
Bottom line
VERSION 1
Researchers at Wuhan University of Bioengineering reported a proof-of-concept HotStart loop-mediated isothermal amplification, or LAMP, assay for Macacine alphaherpesvirus 1, also called B virus or monkey B virus, in Veterinary Sciences. The assay targets a conserved region of the UL1 gene, was optimized at 70 °C with engineered Bst 3.2/4.2 polymerase, and produced both real-time fluorescence readouts and a visible color change, from violet to yellow-green, when viral DNA was present. The authors position it as a simpler, faster molecular testing approach for McHV-1, a macaque-associated zoonotic pathogen that can cause severe, often fatal neurologic disease in humans. (mdpi.com)
Why it matters: For veterinary professionals, especially those working with research primates, diagnostic speed and biosafety are the core issues. CDC says direct culture has been the traditional diagnostic standard, but it requires biosafety level 4 containment, underscoring why lower-complexity molecular options are attractive. A field-friendly or lower-infrastructure assay could support faster screening, triage, and occupational exposure response in macaque facilities, though this study is still an analytical proof of concept rather than a clinical validation in routine practice. (cdc.gov)
What to watch: The next step is whether the assay is validated on larger clinical sample sets and compared head-to-head with established reference testing before it moves into broader veterinary or laboratory use. (cdc.gov)
Key facts
- Study type
- Proof-of-concept analytical validation
- Pathogen
- Macacine alphaherpesvirus 1 (B virus, monkey B virus)
- Journal
- Veterinary Sciences
- Target gene
- UL1
- Assay type
- HotStart loop-mediated isothermal amplification (LAMP)
- Optimization temperature
- 70 °C
- Polymerase
- Engineered Bst 3.2/4.2 DNA polymerase
- Readout
- Real-time fluorescence and color change from violet to yellow-green
- Clinical context
- Macaque-associated zoonotic pathogen that can cause severe, often fatal neurologic disease in humans
A newly published study in Veterinary Sciences describes a HotStart LAMP assay designed to detect Macacine alphaherpesvirus 1, the macaque herpesvirus better known as B virus. The paper, published in September 2026, presents the assay as a proof-of-concept analytical validation targeting the UL1 gene, with the goal of creating a simpler molecular test that can identify viral DNA without the infrastructure demands of conventional high-containment methods. (mdpi.com)
That matters because B virus remains a high-consequence occupational hazard in macaque medicine, laboratory animal care, and primate research. CDC says the virus is endemic in macaques, often causes mild or inapparent infection in its natural host, and can produce severe encephalitis or encephalomyelitis in humans after bites, scratches, mucosal exposure, or contact with infected tissues and fluids. Although human infection is rare, the consequences can be devastating, and rapid diagnosis is considered critical to treatment decisions and exposure management. (cdc.gov)
In the new study, the authors focused on a conserved, moderately GC-rich region of the UL1 gene and optimized the reaction at 70 °C using engineered HotStart Bst 3.2/4.2 DNA polymerase. According to the journal page, the assay supports real-time fluorescence monitoring and a naked-eye colorimetric readout, with positive reactions shifting from deep violet to bright yellow-green. That combination is notable because it points to a test format that could be easier to run outside highly specialized molecular labs, at least in principle. (mdpi.com)
The broader diagnostic backdrop helps explain the interest. CDC notes that direct culture has been the standard for B virus diagnosis, but because of worker safety risks, it requires biosafety level 4 containment. The agency also points laboratories to the National B Virus Resource Center at Georgia State University for diagnostic testing and emergency support. In practice, that means many veterinary and research settings still depend on referral pathways and strict exposure protocols, so any credible assay that reduces turnaround time or expands testing access would draw attention. (cdc.gov)
Independent commentary on this specific paper appears limited so far, which isn't unusual for a study published only days ago. Still, the public health context is well established. CDC’s Emerging Infectious Diseases has described B virus as a severe zoonotic threat tied to macaque exposure, and a 2024 case report from Japan reinforced that workers in macaque facilities remain at risk. More recent surveillance work in Thailand also argued for continued monitoring and genetic analysis of B virus in macaque populations to better manage zoonotic risk. (wwwnc.cdc.gov)
Why it matters: For veterinarians and laboratory animal teams, the potential value here is less about replacing existing reference testing tomorrow and more about adding another tool to the exposure-response toolbox. If future studies show the assay performs well on real-world clinical specimens, it could help support faster screening of macaque colonies, quicker assessment after occupational incidents, or more practical testing in facilities without advanced PCR capacity. That said, this paper reports analytical validation and proof of concept, not broad clinical deployment, so veterinary professionals should view it as an early-stage diagnostic development rather than a ready-to-adopt standard. (cdc.gov)
There are also operational questions still to answer. B virus diagnostics must distinguish McHV-1 from related alphaherpesviruses, fit into existing biosafety workflows, and hold up across specimen types and viral loads likely to be seen in colony surveillance or post-exposure workups. Earlier CDC literature has emphasized that cross-reactivity among primate alphaherpesviruses complicates diagnosis, which raises the bar for any new assay entering this space. (wwwnc.cdc.gov)
What to watch: The key milestones will be expanded validation, peer comparison with established molecular or reference-lab methods, and any evidence that the assay can be integrated into occupational health and nonhuman primate veterinary workflows without compromising sensitivity, specificity, or biosafety. (cdc.gov)